Photo from wikipedia
Direct‐acting antivirals (DAAs), including sofosbuvir (SOF), are recommended for treatment of chronic hepatitis C virus (HCV) infection. However, few studies have investigated the effectiveness and safety of new DAAs in… Click to show full abstract
Direct‐acting antivirals (DAAs), including sofosbuvir (SOF), are recommended for treatment of chronic hepatitis C virus (HCV) infection. However, few studies have investigated the effectiveness and safety of new DAAs in kidney transplant recipients (KTRs).
Keywords:
effectiveness safety;
infection;
sofosbuvir;
chronic hepatitis
Journal Title: Transplant Infectious Disease
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transplant Infectious Disease
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!